Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Deloitte
US Army
Fish and Richardson
Cantor Fitzgerald
McKesson
Daiichi Sankyo
Healthtrust
Fuji

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TORISEL

« Back to Dashboard

Clinical Trials for Torisel

Trial ID Title Status Sponsor Phase Summary
NCT00016328 CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Completed National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of CCI-779 in treating patients who have recurrent glioblastoma multiforme. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00028028 CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 Randomized phase II trial to compare the effectiveness of different doses of CCI-779 in treating patients who have extensive-stage small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
NCT00033267 CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of CCI-779 in treating patients who have mantle cell non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
NCT00072176 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed National Cancer Institute (NCI) Phase 2 This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back after a period of time during which the cancer could not be detected. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00075647 CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed National Cancer Institute (NCI) Phase 2 Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well CCI-779 works in treating patients with locally advanced or metastatic pancreatic cancer
NCT00079235 CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well CCI-779 works in treating patients with stage IIIB non small cell lung cancer (with pleural effusion) or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die. CCI-779 may also stop the growth of tumor cells by blocking the enzymes necessary for their growth.
NCT00079456 Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well temsirolimus works in treating patients with relapsed or refractory multiple myeloma. Drugs used in chemotherapy such as temsirolimus work in different ways to stop cancer cells from dividing so they stop growing or die.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Torisel

Condition Name

Condition Name for Torisel
Intervention Trials
Advanced Cancer 7
Adult Gliosarcoma 6
Recurrent Melanoma 6
Adult Glioblastoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Torisel
Intervention Trials
Carcinoma 26
Carcinoma, Renal Cell 19
Lymphoma 16
Neoplasms 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Torisel

Trials by Country

Trials by Country for Torisel
Location Trials
United States 731
Canada 46
France 19
Japan 19
Australia 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Torisel
Location Trials
Texas 46
California 32
Pennsylvania 29
Illinois 28
Minnesota 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Torisel

Clinical Trial Phase

Clinical Trial Phase for Torisel
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 55
[disabled in preview] 70
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Torisel
Clinical Trial Phase Trials
Completed 66
Active, not recruiting 24
Recruiting 14
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Torisel

Sponsor Name

Sponsor Name for Torisel
Sponsor Trials
National Cancer Institute (NCI) 66
M.D. Anderson Cancer Center 17
Pfizer 16
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Torisel
Sponsor Trials
Other 75
NIH 66
Industry 43
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Teva
Julphar
Cantor Fitzgerald
Argus Health
Baxter
US Army
Chubb
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.